Initiates Coverage on NanoViricides (NYSE:NNVC) assumed coverage on shares of NanoViricides (NYSE:NNVCFree Report) in a report published on Sunday. The firm issued a sell rating on the stock.

NanoViricides Stock Performance

NNVC opened at $2.42 on Friday. The business has a 50 day moving average price of $1.61 and a 200 day moving average price of $1.30. NanoViricides has a twelve month low of $1.00 and a twelve month high of $2.49. The firm has a market cap of $28.58 million, a P/E ratio of -2.95 and a beta of 0.93.

NanoViricides (NYSE:NNVCGet Free Report) last posted its earnings results on Wednesday, May 15th. The company reported ($0.16) earnings per share for the quarter.

NanoViricides Company Profile

(Get Free Report)

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.

Featured Stories

Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with's FREE daily email newsletter.